LON:SBTX SkinBioTherapeutics Interim Earnings Report GBX 9.75 +0.05 (+0.52%) As of 04/1/2026 ProfileEarnings History SkinBioTherapeutics EPS ResultsActual EPS-GBX 0.46Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ASkinBioTherapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASkinBioTherapeutics Announcement DetailsQuarterInterimDate3/26/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile SkinBioTherapeutics Earnings HeadlinesSkinBioTherapeutics Finalises Financial Investigation and Appoints New Auditor Ahead of Results Publication (SBTX)May 28, 2026 | uk.finance.yahoo.comSkinBioTherapeutics shares jump 10% as mystery investor builds 22% stake through company crisisMarch 13, 2026 | uk.finance.yahoo.comTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, Jensen Huang, Tim Cook, and the CEOs of BlackRock, Goldman Sachs, and CitiBank. The media covered the handshakes. But what was really being negotiated behind closed doors? Porter Stansberry has connected the Beijing trip to a landmark pact signed by 13 nations in Washington - a pact designed to cut China out of a $3 trillion investment wave tied to the most critical resource of the 21st century. His new documentary exposes the five assets at the center of it all.June 4 at 1:00 AM | Porter & Company (Ad)AIM Market Roundup: IQE, System1, SkinBioTherapeuticsMarch 3, 2026 | uk.finance.yahoo.comSkinBioTherapeutics warns on profit amid misconduct probe against former CEOFebruary 17, 2026 | msn.comSkinBioTherapeutics forced to reverse royalty income statementFebruary 16, 2026 | uk.finance.yahoo.comSee More SkinBioTherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like SkinBioTherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SkinBioTherapeutics and other key companies, straight to your email. Email Address About SkinBioTherapeuticsSkinBioTherapeutics (LON:SBTX), a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.View SkinBioTherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro in FocusMedtronic Bottoms, Healthy Rebound AheadFrom Runway to Riches: Victoria's Secret's New LookDell's AI Toll Bridge Is Paved with Record MarginsGitLab’s Price Recovery Gains Traction—Time to Get On Board?Ulta's Q1 Report Primes It for a Beauty of a ReboundPalo Alto Networks Accelerates Growth 31% on AI Demand Upcoming Earnings Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
